Multiple Myeloma
Conditions
Brief summary
Multiple myeloma (MM) is a disease caused by malignant plasma cell proliferation disorder. Survival outcomes continue to vary widely even within uniformly treated clinical trial populations. How to construct a clinical prognosis model of MM through real-world data to guide the selection of treatment options, standardize patient management, and improve survival expectations, is a major problem that needs to be solved urgently. It is necessary to build an MM-specific cohort in China to comprehensively understand the characteristics of MM patients, explore treatment options, and improve prognostic factors for survival outcomes.
Interventions
None listed
Sponsors
The First Affiliated Hospital of Soochow University
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
Patients were diagnosed as multiple myeloma from January 1, 2008 (the diagnostic criteria are based on Chinese Guidelines for the Diagnosis and Treatment of Multiple Myeloma (Revised in 2020)).
Exclusion criteria
Long-term follow-up information for patients is not available for any reason, such as not being available or having a serious concomitant disease.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall survival | 5 years | Overall survival is defined as the time from being treated to death from any cause. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progression free survival(PFS) | 5years | Progression-free survival (PFS) is defined as the time from being treated to disease progression or death from any cause. |
Countries
China
Outcome results
None listed